Release Date:  January 21, 2000

RFA:  DA-00-008

National Institute on Drug Abuse

Letter of Intent Receipt Date:  March 13, 2000
Application Receipt Date:       April 12, 2000


The National Institute on Drug Abuse (NIDA) invites applications for Centers 
for Drug Abuse and AIDS Research (CDAAR) Core Grants (P30) in support of a 
large number of active research projects that are funded by the National 
Institutes of Health or other federal or non-federal sources.   The purpose 
of the CDAAR Core Grants is to create centers  to enhance basic, clinical, 
epidemiological, prevention, and applied research on drug abuse and HIV 
infection and other co-occurring illnesses, through the support of shared 
resources.  The joint focus on drug abuse and HIV/AIDS focus distinguishes 
these applications from the more general HIV/AIDS focus of the Centers for 
AIDS Research (CFARs) sponsored by the National Institute of Allergy and 
Infectious Diseases.

Any single CDAAR must integrate a predominant theme or focus; e.g., the 
delivery of primary care and prevention services to drug abusers not in 
treatment, the cognitive or behavioral problems in drug abusers with 
implications for HIV/AIDS.  Relevant multidisciplinary efforts would be 
expected to address and complement the central theme; e.g., pharmacologic 
studies of the interactions of Highly Active Antiretroviral Therapy (HAART) 
with drugs of abuse in drug users not in treatment, studies of community 
based prevention in this population, clinical studies of nutritional and 
neuroendocrine factors related to disease progression.  NIDA provides support 
for research center grants to foster a synergistic approach to drug abuse and 
HIV/AIDS research and to enable studies that would not occur without the 
climate, facilities, and research resources that a research center can 
uniquely provide. NIDA encourages the application of multiple scientific 
perspectives and approaches to the intertwined problems of drug abuse and 
HIV/AIDS. NIDA's CDAAR Core Grant program is intended to support the highest 
quality, multidisciplinary research centers. 

CDAARs must have two sets of essential and defining qualities. The first of 
these is, of course, the highest caliber of scientific work. The second set 
relates to the particular characteristics of research centers, as opposed to 
simply outstanding work supported through other grant mechanisms. This set of 
center-specific characteristics emerges from the confluence of thematic 
integration, synergy, and multidisciplinary involvement. Research supported 
at a CDAAR must be thematically focused and must reflect, or come to reflect 
over time, clear interdependence of components of the research program that 
would not occur simply from the mere collection of the individual components. 
Taken as a whole, a CDAAR is expected to enable a level of achievement which 
exceeds that expected on the basis of the “sum of its parts.”  Center support 
should be essential to the achievement of work that is proposed. 

In addition, CDAARs are expected to serve as national research resources. 
They are expected to attract established and promising investigators into 
drug abuse and HIV/AIDS research. Through the CDAARs, NIDA seeks to encourage 
outstanding scientists to bring a full range of expertise, approaches, 
technologies, and creativity to the study of problems related to drug abuse 
and HIV/AIDS. Investigative efforts are expected to be broadly based and to 
encompass a variety of areas, including biological, biomedical, social, 
behavioral, and/or clinical sciences and to address critical issues of 
neuroscience, prevention, treatment, health services, or other drug abuse and 
HIV/AIDS-related research areas. 

Further information on expected characteristics of NIDA Centers, including 
CDAAR Core Grants, may be found in the NIDA Research Center Grant 
Consolidated Program and Review Guidelines that are available at: 


The Public Health Service (PHS) is committed to achieving the health 
promotion and disease prevention objectives of “Healthy People 2000,” a PHS-
led national activity for setting priority areas.  This RFA, “Centers for 
Drug Abuse and AIDS Research Core Grants,” is related to the priority area of 
alcohol and other drugs.  Potential applicants may obtain a copy of Healthy 
People 2000 at  


Applications may be submitted by domestic, for-profit and non-profit 
organizations, public and private, such as universities, colleges, hospitals, 
laboratories, units of state and local governments, and eligible agencies of 
the federal government.  Racial/ethnic minority individuals, women, and 
persons with disabilities are encouraged to apply as Principal Investigators.  
Foreign institutions are not eligible to apply, but CDAAR Core Grants may 
include research projects located at foreign sites.


The support mechanism for this initiative is the P30 Center Core Grant  (see 
SPECIAL REQUIREMENTS below).  Responsibility for the planning, direction, and 
execution of the proposed project will be solely that of the applicant.  The 
total project period for an application submitted in response to this RFA may 
not exceed 3 years.  This RFA is a one-time solicitation.  The anticipated 
award date September 29, 2000.

The CDAAR Core Grants are intended to bring together investigators currently 
supported by other sources to enhance and extend the effectiveness of 
research related to drug abuse and AIDS.  The applicant may propose pooling 
existing core resources of currently funded grantees and request additional 
support for developing a research infrastructure to be shared by them.  This 
research infrastructure support may include, for example, administrative 
coordination, subject recruitment, equipment, laboratories, statistical 
analysis and database management, and similar shared resources.  It should be 
made clear how core center support would enhance the individually funded 
projects’ contributions and result in programmatic coherence, synergy, and 
integration.  Applicants must demonstrate the potential for continuation of 
funding of projects included in the application, and there must be at least 2 
years of funding left at the time of submission for each project identified 
in the application.


NIDA intends to commit approximately $3,000,000 in FY 2000 to fund 
approximately five new grants in response to this RFA.  An applicant may 
request a project period of up to 3 years and a budget for direct costs 
consistent with the work proposed.  Because the nature and scope of the 
research proposed may vary, it is anticipated that the size of the award will 
also vary.  Although the financial plans of NIDA provide support for this 
program, awards pursuant to this RFA are contingent upon the availability of 
funds and the receipt of a sufficient number of applications of outstanding 
scientific and technical merit.  At this time, it is not known if competing 
renewal applications will be accepted and/or if this RFA will be reissued. 



The relationship between drug abuse and HIV/AIDS has long been recognized.  
Issues related to HIV natural history and epidemiology, etiology and 
pathogenesis, and treatment in drug abusers, their sexual partners, and their 
children have been studied by many researchers from many perspectives.  
However, often drug abuse issues are not fully integrated into the research 
design and conceptualization.  Where drug abuse concerns are integral to the 
research, there is often a lack of infrastructure support to efficiently and 
effectively facilitate the needed studies, as well as provide a 
multidisciplinary environment that stimulates exceptional creativity and 
integration of approaches.  This RFA attempts to foster the unique 
environment of a center, which stimulates work of the highest quality and 
where synergism results in achievements beyond those expected if the projects 
exist in isolation from one another.  

Examples of current areas of NIDA-supported drug abuse research that are 
considered HIV/AIDS-related and may serve as the focus of CDAARs or projects 
within CDAARS include those listed below, as well as cross cutting areas of 
relevance; i.e., racial/ethnic factors, underrepresented or minority status, 
socioeconomic and cultural factors, gender differences, and issues that are 
unique to women and to men.  For example, gender-related research has shown 
that women's HIV viral loads are not the same as men's, raising the issue of 
whether women may need earlier interventions with anti-viral therapies. 
Another example may be a field such as genetics in which the rapid 
development of knowledge as well as technology (e.g., gene chip arrays, 
quantitative trait locus analysis) may be broadly applicable to a number of 
research areas. As relevant data emerge from laboratory, community-based, and 
clinical HIV/AIDS research, investigators are urged to include these and 
other cross cutting perspectives in their research designs and analyses, 
where appropriate. More details on these areas of interest and on drug abuse 
are available at the following website: 

Natural History and Epidemiology:

International and national studies of the epidemiology and natural history of 
HIV and associated infectious diseases (e.g., hepatitis, sexually transmitted 
diseases, tuberculosis) and other co-morbid diseases (e.g., mental disorders) 
in drug abusing populations; and studies of health seeking behaviors, 
adherence to treatment regimens, access to treatment, and the organization 
and management of the delivery of prevention and treatment services to drug 
abusers at risk for HIV or who are HIV positive.

Etiology and Pathogenesis:

Studies to define the role of drugs of abuse and related compounds or drug 
abuse treatment medications on susceptibility, onset, and progression of HIV 
disease, including studies to identify latent HIV infection and 
pharmacotherapy-resistant HIV strains in drug abusing populations; and 
studies to identify and elucidate the interaction between abused drugs and 
cellular and molecular events (i.e., protein kinase function) which may 
modulate host defenses against opportunistic infections and other HIV co-
morbid conditions.

Research to improve access to health services provided to and long-term 
therapeutic strategies designed for HIV-infected drug users, their sexual 
partners, and their children, including studies of adherence, recruitment and 
retention, service delivery models, evaluation of alternative and 
complementary therapies, and evaluation of interactions among drugs of abuse, 
medications used to treat drug abuse, and HIV pharmacotherapies; and studies 
on recruitment of drug abusers into clinical trials.


Research on improving behavioral and/or biomedical methods to deliver HIV and 
other infectious disease vaccines to adolescent and adult drug-using 
populations; research to recruit injection and non-injection drug users at 
high risk of HIV infection into clinical trials of vaccines, including 
developing specific strategies to study children, adolescents, and adults; 
and   investigation of how drugs of abuse may affect or modulate cofactors 
for HIV transmission.  Those cofactors include, for example, vaginal/cervical 
epithelium changes during puberty; hormonal changes during pregnancy; and use 
of contraceptives, hormonal replacement therapy, or steroids.

Behavioral and Social Science Research:

Research to develop, evaluate, and disseminate prevention strategies to 
reduce the incidence of drug use-related HIV infection, including high risk 
drug use-associated sexual behavior (e.g., among adolescents, in perinatal 
transmission in drug-abusing mothers, and in commercial sex work); and 
research to inform and improve our understanding of behavior change, the 
maintenance of behavior change, and risk avoidance and relapse prevention 
relative to the prevention of drug use-related HIV transmission.

Information Dissemination:

Research on mass media and other education strategies focused on AIDS and 
drug abuse in children (ages 8-12), adolescents, adults, racial/ethnic 
groups, and gender specific groups; and studies of HIV and drug use 
prevention strategies for community-based organizations, health care service 
providers, practitioners, and other clinical and public health professionals 
involved in HIV prevention, risk reduction, and/or drug abuse and HIV/AIDS 
treatment that targets high risk and hard-to-reach community populations.

Research Ethics:

 Studies of the ethical, legal, and social interactions and resulting issues 
related to research on HIV/AIDS and drug abuse in diverse settings (i.e., the 
community, the street setting, or the clinic).  Investigators are referred 
for general topic areas and more background information to the program 
announcement Research on Ethical Issues in Human Studies (PA-99-079), 
available at:

International Research Collaboration:

Research support for collaborative national and international research with a 
focus on drug abuse-related links to HIV/AIDS.  International collaborative 
research may involve, for example, any of the above areas (e.g, etiology and 
pathogenesis, natural history/epidemiology, vaccines, social and behavioral 
sciences, information dissemination, research ethics).

The above areas are provided as examples, but they are not meant to be 
comprehensive or to imply the absence of potential interest in other areas.  
Thus, consultation with NIDA staff is encouraged as an early step in the 
development of CDAAR applications.


NIDA has a number of special requirements for its centers, and applicants 
should carefully read the aforementioned NIDA Research Center Grant 
Consolidated Program and Review Guidelines, which are available at:  Consistent with this document, 
CDAAR Core Grants are expected to enable centers that demonstrate the 
occurrence of consistent, thematically focused, and creative research 
productivity that emerges from interdependent components of the research 
program and that would not emerge from the mere collection of those 
individual components. The three necessary characteristics of NIDA centers--  
thematic integration, synergy, and multidisciplinary involvement-- should be 
present.  Although center support is not intended to support direct research 
activities in P30s, there should be evidence that the support of the core 
activities enables the implementation of associated research and that this 
research is innovative and of the highest caliber. Applicants must 
demonstrate that the CDAAR would serve as a significant national scientific 
research resource soon after establishment. 

The CDAAR Core Grant will support “core” components.  Each core component 
should contribute toward cost-effectiveness and quality control in resource 
utilization. Data analytic capacities, database facilities, and data 
resources should be specified as needed. Provisions for shared laboratory 
resources and the quality of laboratory space should be indicated. Similar 
information should be provided for clinical facilities.

The CDAAR Core Grant must be predicated on the existence of active and sound 
research projects that will share the resources supported under the grant.  
NIDA does not specify a minimum number of research projects or cores to 
include in its centers, but it is required that the proposed configuration 
clearly demonstrate appropriate and adequate facilities dedicated to the 
conduct of administrative, shared resource, and research activities.  At the 
time of submission, all research projects participating in the CDAAR Core 
Grant should have at least 2 years of funding left, with clear plans for 
continuing or expanding the work.

In order to evaluate the application, it should include sufficient detail to 
document the significance and aims of the studies, as well as describe the 
involved populations, design and methods, and anticipated uses of core 

Each CDAAR must have a scientifically and administratively qualified director 
with responsibility for the scientific, administrative, budgetary, and 
operational aspects of the CDAAR. The CDAAR director should be a productive 
(as documented by publications, patents, honors, and similar indices of 
stature) researcher. The CDAAR director is responsible for overall 
coordination and for the development of the CDAAR.

Because of the role and importance of the CDAAR director to the success of 
the center, an individual may not serve as director of more than one NIDA 
research center grant. In addition, it is expected that the CDAAR director 
will make a substantial commitment of time and effort to the CDAAR. 

A detailed description of each core unit proposed must be provided with a 
detailed budget and justification (see APPLICATION PROCEDURES for more 
details).  The description should include a rationale to show how each core 
will support the research effort and contribute to the characteristics of 
NIDA centers.  Funds for new construction will not be provided.  

The CDAAR must have appropriate and effective administrative and 
organizational capabilities to conduct research, to foster synergy, and to 
plan and evaluate CDAAR activities. There should be clear and convincing 
evidence of the applicant institution's commitment to the CDAAR. 
Administrative and organizational arrangements should promote joint planning 
and evaluation activities, as well as collaborations and interactions within, 
among, and between programmatic elements of the CDAAR. This should include: 
(a) an overall programmatic structure that effectively promotes scientific 
interactions, provides for internal quality control of research, produces 
publications, generates future grant applications, and also takes maximum 
advantage of the CDAAR's drug abuse and HIV/AIDS research capability (this is 
particularly important to explain when there are multiple participating 
institutions in the CDAAR); (b) an administrative organization that has clear 
lines of authority, is managed efficiently and cost effectively, and enables 
effective use and leverage of resources; (c) a standing outside advisory 
structure(s) that is charged to provide appropriate and objective advice and 
evaluation, as needed, to the center director; (d) internal advisory, 
decision-making, and priority setting processes appropriately charged to 
conduct the activities of the center; and (e) appropriate criteria and 
processes for determining and sustaining individual participation in the 
center based on productivity, research direction, and overall contribution.  
Administrative support might also include plans for recruitment, training, 
and supervision of staff. 

If a CDAAR applicant wishes to identify a General Clinical Research Center 
(GCRC) or comparably supported clinical research facility as a source for 
conducting proposed research, a letter of agreement from the program director 
or principal investigator of the GCRC or comparably supported clinical 
research facility should be included in the application material. 

Support for one 2-day meeting of the CDAAR director with other CDAAR 
directors should be requested.  NIDA anticipates holding one such meeting a 
year in the Washington, D.C., area.


It is the policy of the NIH that women and members of minority groups and 
their subpopulations must be included in all NIH supported biomedical and 
behavioral research projects involving human subjects, unless a clear and 
compelling rationale or justification is provided that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of 
the research.  This new policy results from the NIH Revitalization Act of 
1993 (Section 492B of Public Law 103-43).

All investigators proposing research involving human subjects should read the 
“NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical 
Research,” published in the Federal Register on March 28, 1994 (FR 59 14508-
14513) and in the NIH Guide for Grants and Contracts, Volume 23, Number 11, 
March 18, 1994, available on the Web at:


It is the policy of NIH that children (i.e., individuals under the age of 21) 
must be included in all human subjects research, conducted or supported by 
the NIH, unless there are scientific and ethical reasons not to include them.  
This policy applies to all initial (Type 1) applications  submitted for 
receipt dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
“NIH Policy and Guidelines on the Inclusion of Children as Participants in 
Research Involving Human Subjects” 
that was published in the NIH Guide for Grants and Contracts, March 6, 1998, 
and is available at the following URL address:

Investigators also may obtain copies of these policies from the program staff 
listed under INQUIRIES.  Program staff may also provide additional relevant 
information concerning these policies.


The National Advisory Council on Drug Abuse recognizes the importance of 
research involving the administration of drugs to human subjects and has 
developed guidelines relevant to such research.   Potential applicants are 
encouraged to obtain and review these recommendations of Council before 
submitting an application that will administer compounds to human subjects.  
The guidelines are available on NIDA’s home page at or may be obtained by calling (301) 443-2755.


Prospective applicants are asked to submit a letter of intent by March 13, 
2000, that includes a descriptive title of the proposed research; the name; 
address, and telephone number of the Center Director, the identities of other 
key personnel and participating institutions; and the number and title of the 
RFA in response to which the application is being submitted.  Although a 
letter of intent is not required, is not binding, and does not enter into the 
review of a subsequent application, the information that it contains allows 
IC staff to estimate the potential review workload and avoid conflict of 
interest in the review.  

The letter of intent is to be sent to the Director, Office of Extramural 
Program Review, as listed under INQUIRIES for review matters, by the letter 
of intent receipt date listed in the heading of this RFA.  


NIDA staff will provide preapplication consultation to all applicants for 
NIDA CDAAR grants. Telephone conversations and meetings with NIDA staff can 
provide information that will be useful to ensure that applications are 
complete and responsive. 

The research grant application form PHS 398 (rev. 4/98) is to be used in 
applying for these grants.  These forms are available at most institutional 
offices of sponsored research and from the Division of Extramural Outreach 
and Information Resources, National Institutes of Health, 6701 Rockledge 
Drive, MSC 7910, Bethesda, MD 20892-7910; telephone 301 710-0267; e-mail; or they may be downloaded from the Web at 

Applications must be complete in order to be accepted. Applicants are 
encouraged to organize their application by initially presenting the face 
page, the abstract page with key personnel, a table of contents, summary 
budget pages for the entire CDAAR Core Grant, and other documentation 
pertaining to the entire application. This should be followed by an 
introductory section of no more than five pages that addresses the ways in 
which the application meets the essential elements that define a NIDA Center 
and how the application is consistent with the aims of the CDAAR Core Grant 
initiative.  After that introduction, each core should be presented with its 
accompanying individual budget, budget justification, biographical sketches, 
other support information, and planned research activities. For each core 
component, there is a 25 page limit.  Appendix material limits apply to each 
core component separately; each component's appendix may include up to 10 
publications, manuscripts, abstracts, patents, or other printed material 
directly related to the project. Surveys, questionnaires, data collection 
instruments, and clinical protocols may also be submitted in the appendix. 
Original glossy photographs or color images may be included, provided that a 
photocopy (that may be reduced in size) is included within the 25 pages of 
the research plan. Applications exceeding page limits, font limits, or 
appendix limits will be returned to the applicant without review. Appendices 
should not be placed within the body of the application but should be bundled 
separately, component by component. 

The RFA label available in the PHS 398 (rev. 4/98) application form must be 
affixed to the bottom of the face page of the application.  Failure to use 
this label could result in delayed processing of the application such that it 
may not reach the review committee in time for review.  In addition, the RFA 
title and number must be typed on line 2 of the face page of the application 
form and the YES box must be marked. 

The sample RFA label available at: has 
been modified to allow for this change.  Please note this is in pdf format.

Submit a signed, typewritten original of the application, including the 
Checklist, and three signed photocopies in one package to:

BETHESDA, MD  20892-7710
BETHESDA, MD 20817 (For express/courier service)

At the time of submission, two additional copies of the application must be 
sent to: 

Director, Office of Extramural Program Review
National Institute on Drug Abuse
6001 Executive Boulevard., Room 3158, MSC 9547
Bethesda, MD  20892-9547
Rockville, MD 20852  (For express/courier service)

Applications must be received by the application receipt date listed in the 
heading of this RFA.  If an application is received after that date, it will 
be returned to the applicant without review.  The Center for Scientific 
Review (CSR) will not accept any application in response to this RFA that is 
essentially the same as one currently pending initial review, unless the 
applicant withdraws the pending application.  The Center for Scientific 
Review will not accept any application that is essentially the same as one 
already reviewed.  This does not preclude the submission of substantial 
revisions of applications already reviewed, but such applications must 
include an introduction addressing the previous critique.  


Upon receipt, applications will be reviewed for completeness by the CSR and 
responsiveness by NIDA.  Incomplete and/or non-responsive applications will 
be returned to the applicant without further consideration.

Applications that are complete and responsive to the RFA will be evaluated 
for scientific and technical merit by an appropriate peer review group 
convened by NIDA in accordance with the review criteria stated below.  As 
part of the initial merit review, a process will be used by the initial 
review group in which applications receive a written critique and undergo a 
process in which only those applications deemed to have the highest 
scientific merit, generally the top half of the applications under review, 
will be discussed, assigned a priority score, and receive a second level 
review by the National Advisory Council on Drug Abuse.  

Review Criteria

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written comments, reviewers will be asked to discuss the following 
aspects of the application in order to judge the likelihood that the proposed 
research will have a substantial impact on the pursuit of these goals.  Each 
of these criteria will be addressed and considered in assigning the overall 
score, weighting them as appropriate for each application.  Note that the 
application does not need to be strong in all categories to be judged likely 
to have major scientific impact and thus deserve a high priority score.  For 
example, an investigator may propose to carry out important work that by its 
nature is not innovative but is essential to move a field forward. 

Review Criteria for Overall Center Application

o	Significance and relevance of the proposed program to the mission of 
NIDA research. Potential of this program to become a national resource.

o	Potential of the program to foster communication, interaction, 
innovation, and high-quality research so that it will be a thematic 
integrated, synergistic, stimulating, and multidisciplinary program. 
Ability of the program to attract both established and promising new 

o	Scope, breadth, and overall quality of the center's program, the core 
units, and the research projects and the ability to coordinate the 
research projects and core units.

o	Participation of a suitable number of responsible and experienced 

o	Leadership ability and scientific stature of the Center Director, 
his/her ability to meet the program's demands of time and effort, and 
his/her ability to promote the center mission among participants.

o	Presence of structure(s) presenting a clear line of authority for 
effective decision-making process.  Adequacy of oversight structures.

o	Academic and physical environment as it bears on research subjects, 
space, and equipment, as well as on the potential for interaction with 
scientists from other departments and institutions.

o	Arrangements for internal quality control of ongoing research, 
allocation of funds, day-to-day management, contractual agreements, 
internal communication, and cooperation among the investigators in the 

o	Presence of an administrative and organizational structure conducive to 
attaining the objective of the proposed program. 

o	Institutional commitment to the requirements of the program.

o	In addition to the above criteria, in accordance with NIH policy, all 
applications will also be reviewed with respect to the following:

o	The adequacy of plans to include genders, minorities and their 
subgroups, and children as appropriate for the scientific goals of the 
research. Plans for the recruitment and retention of subjects also will 
be evaluated.

o	The reasonableness of the proposed budget and duration in relation to 
the proposed research.

o	The adequacy of the proposed protection for humans, animals, and/or the 
environment to the extent they may be adversely affected by the 
activities proposed in the application.

Review Criteria for Cores

o	Technical merit and justification of each core unit.  Likelihood of the 
cores to successfully attain the proposed objectives.

o	Evidence of cost-effectiveness and documentation of quality control of 
core units.

o	Evidence of sound data collection, analysis, management, and transfer. 

o	The extent to which core units contribute to greater cooperation among 
center investigators.

o	The scientific appropriateness of the research project’s use of core 

o	Qualifications, experience, and commitment to the center mission of the 
investigators responsible for the core unit and their ability to devote 
the required time and effort to the program.

o	Appropriateness of the budget request for the core unit, including 
consideration of overall administrative costs.

o	As appropriate, the adequacy of the means proposed for protecting 
against risks to human subjects, animals, and/or the environment.

o	As appropriate, the adequacy of representation of both genders, 
minorities and their subgroups, and children in study populations.

Review Criteria for Research Projects 

In general, NIH- and National Science Foundation (NSF) funded research 
projects will not be reviewed for scientific and technical merit since they 
have been peer-reviewed before they are funded.  All other funded projects 
will be reviewed for scientific and technical merit using the following 

Significance: Does this study address an important problem? If the aims of 
the application are achieved, how will scientific knowledge be advanced? What 
will be the effect of these studies on the concepts or methods that drive 
this field? 

Approach: Are the conceptual framework, design (including composition of 
study population), methods, and analyses adequately developed, well 
integrated, and appropriate to the aims of the project? Does the applicant 
acknowledge potential problem areas and consider alternative tactics? 

Innovation: Does the project employ novel concepts, approaches, or methods? 
Are the aims original and innovative? Does the project challenge existing 
paradigms or develop new methodologies or technologies?

Investigators: Is the principal investigator appropriately trained and well 
suited to carry out this work? Is the work proposed appropriate to the 
experience level of the principal investigator and other researchers (if 
any)? DO NOT INCLUDE descriptive biographical information unless important to 
the evaluation of merit.

Environment: Does the scientific environment in which the work will be done 
contribute to the probability of success? Do the proposed experiments take 
advantage of unique features of the scientific environment or employ useful 
collaborative arrangements? Is there evidence of institutional support? DO 
NOT INCLUDE description of available facilities or equipment unless important 
to the evaluation of merit. 

In addition to the above criteria, in accordance with NIH policy, projects 
will be reviewed with respect to the  adequacy of plans to include both 
genders, minorities and their subgroups, and children as appropriate for the 
scientific goals of the research.  Plans for the recruitment and retention of 
subjects will also be evaluated. 

Letter of Intent Receipt Date:    March 13, 2000
Application Receipt Date:         April 12, 2000
Peer Review Date:                 Summer 2000
Council Review:                   September 2000
Earliest Anticipated Start Date:  September 29, 2000


Award criteria that will be used to make award decisions include:  scientific 
merit (as determined by peer review), availability of funds, and programmatic 


Inquiries concerning this RFA are encouraged.  The opportunity to clarify 
issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Sander G. Genser, M.D., M.P.H.
Center on AIDS and Other Medical Consequences of Drug Abuse  
National Institute on Drug Abuse
6001 Executive Boulevard, Room 5198, MSC 9593
Bethesda, MD 20892-9593
Telephone :  (301) 443-1801
FAX :  (301) 594-6566
E-mail:  SG73F@NIH.GOV

Direct inquiries regarding fiscal matters to:

Gary Fleming, J.D., M.A.
Grants Management Branch
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3131, MSC 9541
Bethesda, MD  20892-9541
Telephone:  (301) 443-6710
FAX :  (301) 594-6847

Direct inquiries regarding review matters to:

Teresa Levitin, Ph.D.
Office of Extramural Program Review
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3158, MSC 9547
Bethesda, MD  20892-9547
Telephone :  (301) 443-2755
FAX:  (301) 443-0538


This program is described in the Catalog of Federal Domestic Assistance No. 
93.279.  Awards are made under authorization of the Public Health Service 
Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 
USC 241 and 285) and are administered under PHS grants policies and Federal 
Regulations 42 CFR 52 and 45 CFR Part 74.  This program is not subject to the 
intergovernmental review requirements of Executive Order 12372 or Health 
Systems Agency review.

The Public Health Service (PHS) strongly encourages all grant recipients to 
provide a smoke-free workplace and promote the non-use of all tobacco 
products.  In addition, Public Law 103-227, the Pro-Children Act of 1994, 
prohibits smoking in certain facilities (or in some cases, any portion of a 
facility) in which regular or routine education, library, day care, health 
care, or early childhood development services are provided to children.  This 
is consistent with the PHS mission to protect and advance the physical and 
mental health of the American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.